Edwards Lifesciences ROE 2010-2022 | EW

Current and historical return on equity (ROE) values for Edwards Lifesciences (EW) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Edwards Lifesciences ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-09-30 $1.46B $6.22B 24.48%
2022-06-30 $1.46B $5.94B 25.12%
2022-03-31 $1.54B $5.85B 27.54%
2021-12-31 $1.50B $5.84B 28.40%
2021-09-30 $1.48B $5.54B 29.70%
2021-06-30 $1.46B $5.13B 31.50%
2021-03-31 $0.85B $4.66B 19.70%
2020-12-31 $0.82B $4.57B 19.95%
2020-09-30 $0.79B $4.21B 19.73%
2020-06-30 $0.74B $3.84B 18.95%
2020-03-31 $1.11B $3.90B 28.85%
2019-12-31 $1.05B $4.15B 28.09%
2019-09-30 $0.77B $3.82B 22.27%
2019-06-30 $0.73B $3.50B 21.56%
2019-03-31 $0.77B $3.45B 23.37%
2018-12-31 $0.72B $3.14B 22.40%
2018-09-30 $0.71B $3.36B 22.41%
2018-06-30 $0.66B $3.16B 20.98%
2018-03-31 $0.56B $3.25B 18.20%
2017-12-31 $0.58B $2.96B 19.76%
2017-09-30 $0.75B $3.16B 25.99%
2017-06-30 $0.72B $2.94B 26.05%
2017-03-31 $0.66B $2.74B 24.97%
2016-12-31 $0.57B $2.62B 22.62%
2016-09-30 $0.55B $2.69B 22.16%
2016-06-30 $0.53B $2.47B 21.83%
2016-03-31 $0.52B $2.30B 21.66%
2015-12-31 $0.50B $2.50B 21.00%
2015-09-30 $0.46B $2.42B 20.32%
2015-06-30 $0.44B $2.29B 20.14%
2015-03-31 $0.87B $2.21B 41.80%
2014-12-31 $0.81B $2.19B 43.31%
2014-09-30 $0.78B $2.04B 45.42%
2014-06-30 $0.76B $1.92B 48.68%
2014-03-31 $0.31B $1.34B 20.67%
2013-12-31 $0.39B $1.54B 25.29%
2013-09-30 $0.40B $1.44B 26.48%
2013-06-30 $0.40B $1.58B 25.54%
2013-03-31 $0.37B $1.59B 24.50%
2012-12-31 $0.29B $1.48B 19.93%
2012-09-30 $0.27B $1.54B 18.60%
2012-06-30 $0.25B $1.44B 17.98%
2012-03-31 $0.24B $1.39B 17.41%
2011-12-31 $0.24B $1.34B 17.44%
2011-09-30 $0.24B $1.36B 17.68%
2011-06-30 $0.24B $1.39B 17.79%
2011-03-31 $0.24B $1.36B 18.73%
2010-12-31 $0.22B $1.31B 18.20%
2010-09-30 $0.20B $1.23B 17.33%
2010-06-30 $0.23B $1.12B 20.19%
2010-03-31 $0.22B $1.15B 19.80%
2009-12-31 $0.23B $1.16B 22.03%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $47.328B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $220.806B 23.09
Alcon (ALC) Switzerland $34.365B 29.59
STERIS (STE) Ireland $19.157B 23.84
Teleflex (TFX) United States $11.378B 18.46
Fresenius Medical Care AG KGaA (FMS) Germany $9.600B 9.64
Penumbra (PEN) United States $8.008B 1916.82
Globus Medical (GMED) United States $7.483B 38.05
Integer Holdings (ITGR) United States $2.426B 19.47
Glaukos (GKOS) United States $2.281B 0.00
Nevro (NVRO) United States $1.601B 0.00
Paragon 28 (FNA) United States $1.511B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.261B 17.96
Artivion (AORT) United States $0.546B 0.00